Abrogation of TGF-β by antisense oligonucleotide modelates expression of VEGF and increases angiogenic potential in isolated fibroblasts from radiated skin

International Journal of Molecular Medicine

Volumn 22, Issue 4, 2008, Pages 473-480

  Riedel, Katrin ^a   Koellensperger, E ^a   Ryssel, H ^a   Riedel, F ^b   Goessler, U R ^b   Germann, G ^a   Kremer, T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiogenesis; Fibroblasts; Radiation wound; Transforming growth factor ; Vascular endothelial growth factor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL GROWTH; CELL ISOLATION; CELL MIGRATION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MICROARRAY ANALYSIS; MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; RADIATION INJURY; RADIOTHERAPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN INJURY; UPREGULATION; WOUND HEALING;

CELL MOVEMENT; CELL SEPARATION; CULTURE MEDIA, CONDITIONED; CYTOKINES; ENDOTHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 54049134442     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm_00000045     Document Type: Article

References (46)

1. Jung H, Beck-Bornholdt HP, Svoboda V, Alberti W and Herrmann T: Quantification of late complications after radiation therapy. Radiother Oncol 61: 233-246, 2001.
2. Harper JL, Franklin LE, Jenrette JM and Aguero EG: Skin toxicity during breast irradiation: pathophysiology and management. South Med J 97: 989-993, 2004.
3. Bentzen SM, Dorr W, Anscher MS, Denham JW, Hauer-Jensen M, Marks LB and Williams J: Normal tissue effects: reporting and analysis. Sem Radiat Oncol 13: 189-202, 2003.
4. Rodemann HP and Blaese MA: Responses of normal cells to ionizing radiation. Semin Radiat Oncol 17: 81-88, 2007.
5. Fajardo LF, Bathrong M and Anderson RE: Radiation Pathology. Oxford University Press, New York, 2001.
6. Van der Kogel AJ: Radiobiology of normal tissues. In: Basic Clinical Radiobiology. Steel GG (ed). Arnold, London, pp99-107, 1993.
7. Canney PA and Dean S: TGF-beta: a promotor of late connective tissue injury following radiotherapy? Br J Radiol 63: 620-623, 1990.
8. Archambeau JO, Pezner R and Wasserman T: Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys 31: 1171-1185, 1995.
9. Denham JW and Hauer-Jensen M: The radiotherapeutic injury - a complex 'wound'. Radiother Oncol 63: 129-145, 2002.
10. Riedel F, Philipp K, Sadick H, Goesslex U, Hormann K and Verse T: Immunohistochemical analysis of radiation-induced non-healing dermal wounds of the head and neck. In Vivo 19: 343-350, 2005.
11. Herskind C, Bamberg M and Rodemann HP: The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol 174 (Suppl 3): 12-15, 1998.
12. Cordeiro MF, Mead A, Ali RR, Alexander RA, Murray S, Chen C, York-Defalco C, Dean NM, Schultz GS and Khaw PT: Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther 10: 59-71, 2003.
13. Roberts AB and Sporn MB: Transforming growth factor-β. In: The Molecular and Cellular Biology of Wound Repair. Clark RAF (ed). 2nd edition, Plenum Press, New York, pp275-308, 1996.
14. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty JP, Angel P and Heath JK: TGF-β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 6: 1899-1904, 1987.
15. Randall K and Coggle JE: Expression of TGF-beta 1 in mouse skin during the acute phase of radiation damage. Int J Radiat Biol 68: 301-309, 1995.
16. Gauldie J, Galt T, Bonniaud P, Robbins C, Kelly M and Warburton D: Transfer of the active form of TGF-beta 1 gene to newborn rat lung induces changes consistent with broncho-pulmonary dysplasia. Am J Pathol 163: 2575-2584, 2003.
17. O'Sullivan B and Levin W: Late radiation-related fibrosis: pathogenesis, manifestations, and current management. Semin Radiat Oncol 13: 274-289; 2003.
18. Anscher MS, Kong FM, Marks LB, Bentel GC and Jirtle RL: Changes in plasma TGF-beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 37: 253-258, 1997.
19. Martin M, Vozenin MC, Gault N, Crechet F, Pfarr CM and Lefaix JL: Co-activation of AP-1 activity and TGF-beta1 gene expression in the stress response of normal skin cells to ionizing radiation. Oncogene 15: 981-989, 1997.
20. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ and Hutchinson IV: Genotypic variation in the TGF-beta1 gene: association with TGF-beta production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66: 1014-1020, 1998.
21. Andreassen CN, Alsner J, Overgaard J, Herskind C, Haviland J, Owen R, Homewood J, Bliss J and Yarnold J: TGF-beta1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 75: 18-21, 2005.
22. Huang JS, Wang YH, Ling TY, Chuang SS, Johnson FE and Huang SS: Synthetic TGF-beta antagonist accelerates wound healing and reduces scarring. FASEB J 16: 1269-1270, 2002.
23. Philipp K, Riedel F, Germann G, Hörmann K and Sauerbier M: TGF-beta antisense oligonucleotides reduce mRNA expression of MMPs in cultured wound-healing-related cells. Int J Mol Med 15: 299-303, 2005.
24. Philipp K, Riedel F, Sauerbier M, Hörmann K and Germann G: Targeting TGF-β in human keratinocytes and its potential role in wound healing. Int J Mol Med 14: 589-593, 2004.
25. Riedel K, Riedel F, Goessler UR, Germann G and Sauerbier M: TGF-beta antisense therapy increases angiogenic potential in human keratinocytes in vitro. Arch Med Res 39: 45-51, 2007.
26. Stadelmann WK, Digenis AG and Tobin GR: Impediments to wound healing. Am J Surg 176: 39S-47S, 1998.
27. Hippenstiel S, Krull M, Ikemann A, Risau W, Clauss M and Suttorp N: VEGF induces hyperpermeability by a direct action on endothelial cells. Am J Physiol 274: L679-L684, 1998.
28. Defacque H, Piquemal D, Basset A, Marti J and Commes T: TGF-beta1 is an autocrine mediator of U937 cell growth arrest and differentiation induced by vitamin D3 and retinoids. J Cell Physiol 179: 109-119, 1999.
29. Riedel F, Götte K, Li M, Hörmann K and Grandis JR: Abrogation of VEGF expression in HNSCC cell lines decreases endothelial cell proliferation and migration in vitro and in vivo. Int J Oncol 23: 577-583, 2003.
30. Miller SH and Rudolph R: Healing in the irradiated wound. Clin Plast Surg 17: 503-508, 1990.
31. Anscher MS, Crocker IR and Jirtle RL: TGF-beta1 expression in irradiated liver. Radiat Res 122: 77-85, 1990.
32. Barcellos-Hoff M and Dix T: Redox-mediated activation of latent TGF-beta1. Mol Endocrinol 10: 1077-1083, 1996.
33. Anscher MS, Kong FM, Murase T, et al: Short communication normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGF-beta. Br J Radiol 68: 331-333, 1995.
34. Roberts AB, Piek E, Bottinger EP, et al: Is Smad3 a major player in signal transduction pathways leading to fibrogenesis? Chest 120: 43S-47S, 2001.
35. Rabbani ZN, Anscher MS, Zhang X, et al: Soluble TGFb type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Int J Radiat Biol Oncol Phys 57: 563-572, 2003.
36. Shah M, Foreman DM and Ferguson MWJ: Neutratisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous wounds reduces scarring. J Cell Sci 108: 983-1002, 1995.
37. Steed DL: The role of growth factors in wound healing. Surg Clin North Am 77: 575-586, 1997.
38. Zhao LL, Davidson JD, Wee SC, Roth SI and Mustoe TA: Effect of hyperbaric oxygen and growth factors on rabbit ear ischemic ulcers. Arch Surg 129: 1043-1049, 1994.
39. Riedel K, Riedel F, Goessler UR, Holle G, Germann G and Sauerbier M: Current status of genetic modulation of growth factors in wound repair. Int J Mol Med 17: 183-193, 2006.
40. Hernandez A and Evers BM: Functional genomics: clinical effect and the evolving role of the surgeon. Arch Surg 134: 1209-1215, 1999.
41. Khavari PA, Rollman O and Vahlquist A: Cutaneous gene transfer for skin and systemic diseases. J Intern Med 252: 1-10, 2002.
42. Wacheck V: Oligonucleotide therapeutics - an emerging novel class of compounds. Wien Med Wochenschr 156: 481-487, 2006.
43. Wraight CJ and White PJ: Antisense oligonucleotides in cutaneous therapy. Pharmacol Ther 90: 89-104, 2001.
44. Schiavone N, Donnini M, Nicolin A and Capaccioli S: Antisense oligonucleotide drug design. Curr Pharm Des 10: 769-784, 2004.
45. Mirabelli CK, Bennett CF, Anderson K and Crooke ST: In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des 6: 647-661, 1991.
46. Tepper OM and Mehrara BJ: Gene therapy in plastic surgery. Plast Reconstr Surg 109: 716-734, 2002.